Apellis Pharmaceuticals (APLS) Invested Capital: 2020-2025
Historic Invested Capital for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $494.7 million.
- Apellis Pharmaceuticals' Invested Capital rose 108.65% to $494.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $494.7 million, marking a year-over-year increase of 108.65%. This contributed to the annual value of $228.5 million for FY2024, which is 17.49% up from last year.
- According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Invested Capital is $494.7 million, which was up 216.53% from $156.3 million recorded in Q2 2025.
- Over the past 5 years, Apellis Pharmaceuticals' Invested Capital peaked at $494.7 million during Q3 2025, and registered a low of -$334.4 million during Q2 2022.
- Its 3-year average for Invested Capital is $272.4 million, with a median of $237.1 million in 2024.
- Per our database at Business Quant, Apellis Pharmaceuticals' Invested Capital crashed by 160.97% in 2021 and then soared by 794.80% in 2022.
- Apellis Pharmaceuticals' Invested Capital (Quarterly) stood at $198.7 million in 2021, then decreased by 14.49% to $169.9 million in 2022, then rose by 14.51% to $194.5 million in 2023, then increased by 17.49% to $228.5 million in 2024, then skyrocketed by 108.65% to $494.7 million in 2025.
- Its Invested Capital stands at $494.7 million for Q3 2025, versus $156.3 million for Q2 2025 and $164.2 million for Q1 2025.